Business Finance Pipeline Appendices - Sanofi

Sanofi to become a pure-play, science-driven biopharma company focused on innovative medicines and vaccines. Closing of the transaction expected in Q2 20251 at the earliest. …

CouponFollow Extension

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS …

3 weeks from now

2 days ago · Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025. Paris, January 30, 2025

morningstar.com

3%
OFF

Sanofi: Q4 Sales Growth Of 10.3%, 2024 Business EPS Guidance …

3 weeks from now

1 day ago · Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback). 6; Sanofi intends to execute a …

pharmiweb.com

50%
OFF

Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes

3 weeks from now

Oct 30, 2024 · Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in …

forbes.com

3%
OFF

Sanofi: Q4 Sales Growth Of 10.3%, 2024 Business EPS Guidance …

3 weeks from now

2 days ago · Pipeline update Sanofi has 83 projects in a pipeline across four main disease areas (Immunology, Rare diseases, Neurology, and Oncology) and Vaccines, including 38 potential …

sanofi.com

$5.21
OFF

Sanofi Forecasts Stronger Profit Growth, Announces €5 Billion Stock …

3 weeks from now

1 day ago · Investing.com -- Sanofi (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.21 billion) worth of shares this year and may take a more active …

yahoo.com

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS

3 weeks from now

1 day ago · Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales...

globenewswire.com

3%
OFF

Sanofi: Q4 Sales Growth Of 10.3%, 2024 Business EPS Guidance …

3 weeks from now

1 day ago · Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of …

finanznachrichten.de

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS …

3 weeks from now

2 days ago · Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025. Paris, January 30, 2025. Q4: sales growth of …

placera.se

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS

3 weeks from now

Jan 30, 2006 · 1 Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). 2 To facilitate an understanding of operational …

sanofi.com

FAQs about Business Finance Pipeline Appendices - Sanofi Coupon?

Will Sanofi repurchase €5 billion worth of shares this year?

Investing.com -- Sanofi (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.21 billion) worth of shares this year and may take a more active approach to acquisitions in the near term. The move comes as the company prepares to sell a significant stake in its consumer health business. ...

Does Sanofi update or revise its financial statements?

or the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forwa d-looking information or statements.Brand names appearing in this presentation are tradem ...

What is the Sanofi-Aventis Strategic Analysis Report?

This new strategic analysis report sanofi-aventis: Pipeline, Products, Performance, Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. ...

Is Sanofi a good stock to buy?

Jefferies analysts reiterated a Buy rating on Sanofi shares following the report. They believe the company's outlook "suggests potential consensus EPS upgrades" and added that the buyback announcement "should be taken well" by investors. ...

What is the outlook for Sanofi-Aventis?

sanofi-aventis has a particularly strong and broad R&D pipeline, particularly in the metabolism/diabetes area. This, together with the potential for further growth in vaccines, means the outlook for sanofi-aventis for the next few years looks very good. ...

Is Sanofi-Aventis a global company?

It has subsequently been overtaken by Novartis, pushing it to fourth largest overall, but sanofi-aventis can be truly classed as a global company with a worldwide sales and marketing infrastructure. Many of sanofi-aventis' products are facing patent expiry and declining sales. ...